1. Home
  2. SKYE vs ISTR Comparison

SKYE vs ISTR Comparison

Compare SKYE & ISTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • ISTR
  • Stock Information
  • Founded
  • SKYE 2012
  • ISTR 2006
  • Country
  • SKYE United States
  • ISTR United States
  • Employees
  • SKYE N/A
  • ISTR N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • ISTR Major Banks
  • Sector
  • SKYE Health Care
  • ISTR Finance
  • Exchange
  • SKYE Nasdaq
  • ISTR Nasdaq
  • Market Cap
  • SKYE 172.9M
  • ISTR 166.7M
  • IPO Year
  • SKYE N/A
  • ISTR 2014
  • Fundamental
  • Price
  • SKYE $5.80
  • ISTR $18.57
  • Analyst Decision
  • SKYE Strong Buy
  • ISTR Buy
  • Analyst Count
  • SKYE 5
  • ISTR 1
  • Target Price
  • SKYE $18.40
  • ISTR $13.50
  • AVG Volume (30 Days)
  • SKYE 147.7K
  • ISTR 36.8K
  • Earning Date
  • SKYE 11-09-2024
  • ISTR 10-17-2024
  • Dividend Yield
  • SKYE N/A
  • ISTR 2.18%
  • EPS Growth
  • SKYE N/A
  • ISTR N/A
  • EPS
  • SKYE N/A
  • ISTR 1.53
  • Revenue
  • SKYE N/A
  • ISTR $80,646,000.00
  • Revenue This Year
  • SKYE N/A
  • ISTR N/A
  • Revenue Next Year
  • SKYE N/A
  • ISTR $13.81
  • P/E Ratio
  • SKYE N/A
  • ISTR $12.00
  • Revenue Growth
  • SKYE N/A
  • ISTR N/A
  • 52 Week Low
  • SKYE $1.44
  • ISTR $9.07
  • 52 Week High
  • SKYE $19.41
  • ISTR $18.99
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 47.89
  • ISTR 60.97
  • Support Level
  • SKYE $5.71
  • ISTR $17.39
  • Resistance Level
  • SKYE $7.11
  • ISTR $18.09
  • Average True Range (ATR)
  • SKYE 0.62
  • ISTR 0.39
  • MACD
  • SKYE 0.01
  • ISTR -0.03
  • Stochastic Oscillator
  • SKYE 7.22
  • ISTR 78.15

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About ISTR Investar Holding Corporation

Investar Holding Corp is a us-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashiers' checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.

Share on Social Networks: